PROMETHAZINE HYDROCHLORIDE

Post-LOE

promethazine hydrochloride

Hikma

ANDAINJECTIONINJECTABLE

Approved

Sep 1973

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

Drug Shortage Active

PROMETHAZINE HYDROCHLORIDE is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.

PROMETHAZINE HYDROCHLORIDE (promethazine hydrochloride) by Hikma is clinical pharmacology promethazine hydrochloride is a phenothiazine derivative which possesses antihistaminic, sedative, antimotion-sickness, antiemetic, and anticholinergic effects. First approved in 1973.

Drug data last refreshed 4h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Promethazine hydrochloride is a phenothiazine derivative which possesses antihistaminic, sedative, antimotion-sickness, antiemetic, and anticholinergic effects. Promethazine is a competitive H 1 receptor antagonist, but does not block the release of histamine. Structural…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on PROMETHAZINE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.